Immunoprecise(IPA) ZACKS·2025-03-28 14:15分组1 - ImmunoPrecise Antibodies Ltd. reported a quarterly loss of 0.08 per share a year ago [1] - The company's revenues for the quarter ended January 2025 were 4.6 million year-over-year [2] - Over the last four quarters, ImmunoPrecise Antibodies has consistently failed to surpass consensus EPS and revenue estimates [2][6] 分组2 - The stock has increased approximately 7% since the beginning of the year, contrasting with a -3.2% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -5.02 million, and for the current fiscal year, it is -18.02 million [7] - The Medical Info Systems industry, to which ImmunoPrecise belongs, is currently ranked in the top 17% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]